September 23, 2021

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria, Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21.

September 15, 2021

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive mCRPC

Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa

September 8, 2021

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Northstar Medical Radioisotopes and POINT Biopharma today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

September 7, 2021

POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

POINT Biopharma today announced that the Company’s Chief Executive Officer, Dr. Joe McCann will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.

August 13, 2021

POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced financial results for the second quarter...